CN1498107A - 紫杉烷与细胞周期蛋白依赖激酶抑制剂的组合 - Google Patents

紫杉烷与细胞周期蛋白依赖激酶抑制剂的组合 Download PDF

Info

Publication number
CN1498107A
CN1498107A CNA028070380A CN02807038A CN1498107A CN 1498107 A CN1498107 A CN 1498107A CN A028070380 A CNA028070380 A CN A028070380A CN 02807038 A CN02807038 A CN 02807038A CN 1498107 A CN1498107 A CN 1498107A
Authority
CN
China
Prior art keywords
administered
pharmaceutical composition
pyridinol
taxotere
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028070380A
Other languages
English (en)
Chinese (zh)
Inventor
M-C
M-C·比斯里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CN1498107A publication Critical patent/CN1498107A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA028070380A 2001-03-23 2002-03-22 紫杉烷与细胞周期蛋白依赖激酶抑制剂的组合 Pending CN1498107A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US60/277,948 2001-03-23
US30269201P 2001-07-05 2001-07-05
US60/302,692 2001-07-05
US33491601P 2001-12-04 2001-12-04
US60/334,916 2001-12-04

Publications (1)

Publication Number Publication Date
CN1498107A true CN1498107A (zh) 2004-05-19

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028070380A Pending CN1498107A (zh) 2001-03-23 2002-03-22 紫杉烷与细胞周期蛋白依赖激酶抑制剂的组合

Country Status (33)

Country Link
US (2) US20020182204A1 (enExample)
EP (1) EP1372652B1 (enExample)
JP (1) JP2004521140A (enExample)
KR (1) KR100879712B1 (enExample)
CN (1) CN1498107A (enExample)
AR (1) AR034222A1 (enExample)
AT (1) ATE395917T1 (enExample)
AU (1) AU2002312815B2 (enExample)
BR (1) BR0208221A (enExample)
CA (1) CA2441441C (enExample)
CY (1) CY1110449T1 (enExample)
CZ (1) CZ301423B6 (enExample)
DE (1) DE60226710D1 (enExample)
DK (1) DK1372652T3 (enExample)
EA (1) EA007815B1 (enExample)
ES (1) ES2305253T3 (enExample)
HR (1) HRPK20030766B3 (enExample)
HU (1) HU229258B1 (enExample)
IL (2) IL158058A0 (enExample)
ME (1) MEP16408A (enExample)
MX (1) MXPA03007743A (enExample)
NO (1) NO332441B1 (enExample)
NZ (1) NZ527655A (enExample)
PE (1) PE20020907A1 (enExample)
PL (1) PL206118B1 (enExample)
PT (1) PT1372652E (enExample)
RS (1) RS50681B (enExample)
SI (1) SI1372652T1 (enExample)
SK (1) SK287481B6 (enExample)
TW (1) TWI355935B (enExample)
UY (1) UY27220A1 (enExample)
WO (1) WO2002076484A2 (enExample)
ZA (1) ZA200307381B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103442708A (zh) * 2011-04-01 2013-12-11 阿斯利康(瑞典)有限公司 治疗性处理

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217982A1 (en) * 2002-03-06 2003-09-22 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
EP1558242B1 (en) * 2002-11-06 2008-12-24 Cyclacel Limited Combination comprising docetaxel and a cdk inhibitor
ES2390237T3 (es) * 2006-02-10 2012-11-07 Nerviano Medical Sciences S.R.L. Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico
BR112013012313A2 (pt) * 2010-11-19 2019-09-24 Piramal Enterprises Limited combinação farmacêutica de paclitaxel e um inibidor de cdk
MX367640B (es) 2011-11-30 2019-08-29 Astrazeneca Ab Tratamiento combinado del cáncer.
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0888458A4 (en) * 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103442708A (zh) * 2011-04-01 2013-12-11 阿斯利康(瑞典)有限公司 治疗性处理
CN103442708B (zh) * 2011-04-01 2016-11-09 阿斯利康(瑞典)有限公司 治疗性处理

Also Published As

Publication number Publication date
NO20034124L (no) 2003-09-16
TWI355935B (en) 2012-01-11
UY27220A1 (es) 2002-09-30
PT1372652E (pt) 2008-07-24
SK11692003A3 (sk) 2004-03-02
ATE395917T1 (de) 2008-06-15
DE60226710D1 (de) 2008-07-03
CY1110449T1 (el) 2015-04-29
HUP0303589A2 (hu) 2004-03-01
WO2002076484A3 (en) 2003-01-03
KR100879712B1 (ko) 2009-01-22
MXPA03007743A (es) 2004-11-12
BR0208221A (pt) 2004-03-02
EA007815B1 (ru) 2007-02-27
EP1372652B1 (en) 2008-05-21
IL158058A (en) 2010-02-17
NZ527655A (en) 2006-03-31
RS50681B (sr) 2010-06-30
ZA200307381B (en) 2005-03-30
CA2441441C (en) 2009-05-26
KR20030086318A (ko) 2003-11-07
JP2004521140A (ja) 2004-07-15
PL206118B1 (pl) 2010-07-30
HUP0303589A3 (en) 2007-05-02
US20060128640A1 (en) 2006-06-15
SI1372652T1 (sl) 2008-10-31
YU69503A (sh) 2006-08-17
US20020182204A1 (en) 2002-12-05
PL367702A1 (en) 2005-03-07
CA2441441A1 (en) 2002-10-03
EA200301053A1 (ru) 2004-02-26
ES2305253T3 (es) 2008-11-01
SK287481B6 (sk) 2010-11-08
DK1372652T3 (da) 2008-09-22
CZ20032551A3 (en) 2004-07-14
HRPK20030766B3 (en) 2006-11-30
NO20034124D0 (no) 2003-09-16
PE20020907A1 (es) 2002-12-19
NO332441B1 (no) 2012-09-17
HRP20030766A2 (en) 2005-06-30
EP1372652A2 (en) 2004-01-02
HU229258B1 (en) 2013-10-28
AU2002312815B2 (en) 2006-08-24
CZ301423B6 (cs) 2010-02-24
MEP16408A (en) 2010-10-10
AR034222A1 (es) 2004-02-04
WO2002076484A2 (en) 2002-10-03
IL158058A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
Li et al. Systemic chemotherapy for the treatment of metastatic melanoma
JP2020524698A5 (enExample)
HU223773B1 (hu) Taxánszármazékokat tartalmazó tumorellenes készítmények
JP2009536956A (ja) 抗癌治療法
EP2254570A1 (en) Combination comprising paclitaxel for treating ovarian cancer
Kobayashi et al. Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan
AU2002312815B2 (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
AU744095B2 (en) Methods and compositions for treatment of ovarian cancer
AU2002312815A1 (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
Georgoulias Docetaxel (taxotere) in the treatment of non-small cell lung cancer
Ghaemmaghami et al. New agents in the treatment of small cell lung cancer
Bleickardt et al. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
CN1471396A (zh) 用于治疗癌症的含喜树碱和1,2-二苯乙烯衍生物的组合物
Choy et al. A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non–Small-Cell Lung Cancer: A Vanderbuilt Cancer Center Affiliate Network (VCCAN) Trial
Bekaii-Saab et al. Preclinical experience with docetaxel in gastrointestinal cancers
CN115414359A (zh) 一种具有增效减毒作用的抗肿瘤药物组合
WO2009104152A1 (en) Combination treatment for ovarian cancer
Hanauske Recent advances in anticancer drug development
Ramaswamy et al. Docetaxel: A tubulin-stablizing agent approved for the management of several solid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication